SCHEDULE: Polar Capital Discloses 8.47% Stake in Enliven Therapeutics

Polar Capital Holdings Plc, Polar Capital LLP, and Polar Capital Funds PLC - Biotechnology Fund have jointly reported a beneficial ownership of 8.47% in Enliven Therapeutics, Inc.

Summary

• Polar Capital Holdings Plc, Polar Capital LLP, and Polar Capital Funds PLC - Biotechnology Fund have filed a Schedule 13G, indicating a significant ownership stake in Enliven Therapeutics, Inc.
• The reporting entities collectively beneficially own 5,065,933 shares of Enliven Therapeutics' common stock.
• This ownership represents 8.47% of the total outstanding shares, based on the issuer's Form 10-Q filed on May 7, 2026.
• The reporting persons have sole voting power and sole dispositive power over these shares.
• The filing is an amendment to a previous filing, with the event date requiring this statement being March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it indicates significant institutional investment but provides no direct operational or financial performance data for Enliven Therapeutics itself.

Positives

• Significant institutional ownership by Polar Capital, suggesting confidence in Enliven Therapeutics' long-term prospects.
• The reporting entities hold sole voting and dispositive power, indicating direct control over their investment decisions.
• The ownership percentage of 8.47% is substantial and positions Polar Capital as a key stakeholder.

Risks

• The filing does not contain specific forward-looking statements or risk factors related to Enliven Therapeutics' business operations. The risks would be detailed in Enliven Therapeutics' own SEC filings.
• Potential for increased volatility in Enliven Therapeutics' stock price due to significant institutional trading activity.

Future Outlook

This filing is a disclosure of ownership and does not contain forward-looking statements or guidance from Enliven Therapeutics. The future outlook for the company would be found in its own periodic SEC filings.

Industry Context

StockSavvy.ai notes that significant Schedule 13G filings often signal increased institutional interest or a shift in ownership structure within the biotechnology sector, which is characterized by high growth potential and inherent risks.

Stakeholder Impact

• Shareholders: May view increased institutional ownership positively, potentially leading to greater liquidity and market interest. However, it could also signal a shift in control dynamics.
• Management of Enliven Therapeutics: Will need to engage with significant institutional investors like Polar Capital.
• Potential Investors: This filing highlights Enliven Therapeutics as a company attracting substantial investment from specialized funds.

Next Steps

• Monitor future filings by Enliven Therapeutics for operational updates and financial performance.
• Observe any further changes in Polar Capital's ownership stake in Enliven Therapeutics.

Key Dates

Keywords

Enliven Therapeutics, Polar Capital, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Biotechnology Fund